Omada Health (OMDA) Q1 2026 Earnings Transcript

Omada Health posted Q1 revenue of $78 million, up 42% year over year, with adjusted EBITDA turning positive at $1 million and GAAP net loss narrowing to $3 million. The company raised full-year revenue guidance to $322 million-$330 million from $312 million-$322 million and lifted adjusted EBITDA guidance to $14 million-$20 million, supported by new PBM partnerships, GLP-1 prescribing capabilities, and accelerating AI-driven efficiency gains. Gross margin expanded to 62% GAAP and 64% non-GAAP, while cash stood at $212 million with no debt.

Analysis

The real signal is not the quarter itself, but the change in Omada’s economic mix: a larger installed base is moving into lower-service, higher-margin years exactly as new distribution channels broaden the addressable funnel. That creates a nonlinear earnings setup where revenue per member can look “slower” while incremental profitability inflects higher, which is the kind of transition the market often underprices until the second derivative shows up in subsequent quarters.

The PBM wins matter more as a channel-control story than as near-term revenue. By plugging into the largest prescription rails, Omada is converting itself from a point solution into an embedded workflow partner, which should raise switching costs and reduce CAC volatility over time; the second-order effect is that competitors without pharmacy or employer distribution breadth will face rising sales friction just as employers become more selective about GLP-1 spend. The most important timing issue is that the new prescribing economics are deferred, so 2026 may understate the strategic value even if the platform is already expanding its pipeline.

AI is the margin wildcard, but the market may be extrapolating too simplistically. The opportunity is less about headline automation and more about shrinking the labor intensity of care delivery while preserving clinical outcomes; if that continues, gross margin could move above the current long-term target faster than modeled. The risk is that adoption, utilization, and shipping/device costs are all front-loaded and can mask the durability of the margin gains if enrollment growth slows or if payers push back on GLP-1 economics.

Consensus may be underappreciating how much of the value creation is now tied to 2027, not 2026. If management executes, the stock can rerate on visibility to a larger installed base monetizing through richer channel mix and higher gross-profit-per-member, but the near-term setup remains vulnerable to any sign that GLP-1 demand is plateauing or that employer decisions slip back into the next renewal cycle.

Key Decisions for Investors

• Long OMDA on pullbacks over the next 2-6 weeks; thesis is multiple expansion from mix shift and 2027 visibility, with downside protected by cash/no debt and improving EBITDA. Use a 3-6 month horizon; trim if the stock rerates ahead of further channel proof.
• Pair trade: long OMDA / short a basket of lower-margin digital health names with weaker distribution moats over 3-9 months. The relative trade benefits if investors start rewarding embedded PBM access and operating leverage rather than top-line growth alone.
• Buy OMDA call spreads dated after the next two earnings cycles to express the 2027 monetization gap without paying for full multiple expansion. Best setup is 6-12 month tenor, targeting a rerating if gross margin guidance moves higher at the investor day.
• Avoid chasing LLY on this print; the incremental value from employer-direct channels is strategically supportive but too delayed to move 2026 economics. Any trade in LLY should be based on broader GLP-1 franchise durability, not this partnership alone.
• Watch for a tactical short if OMDA spikes on the release and fails to hold gains into the next enrollment commentary; the risk/reward on an overextended move is poor because the near-term number already benefited from sentiment and investors may realize the revenue ramp is back-half weighted.